Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04439279 · FLOW

Participant flow

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) · Source last updated 2026-05-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Subprotocol R
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        17
      type
      Disease progression
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Complicating disease
    5. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Withdrawal by Subject
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Ineligible
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Treatment still ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        33
      type
      Eligible
    4. achievements
      1. comment
        Adverse event was not assessed on one patient before discontinuing therapy due to withdraw/refusal
        group Id
        FG000
        num Subjects
        34
      type
      Reported Adverse Events Data
    5. achievements
      1. comment
        Treatment continued until disease progression or intolerability.
        group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    6. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol R, patients had to have BRAF fusion or Non-V600E, Non-V600K mutations.
recruitment Details
Subprotocol R was activated on August 12, 2015. A total of 50 patients were assigned to this arm after screening, 48 from screening cohort and 2 from outside assay. Of the 50 patients, 35 patients were enrolled to arm R between December 4, 2015 and August 17, 2017.
Complete source fields
groups
  1. description
    Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Subprotocol R
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        17
      type
      Disease progression
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Complicating disease
    5. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Withdrawal by Subject
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Ineligible
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Treatment still ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        33
      type
      Eligible
    4. achievements
      1. comment
        Adverse event was not assessed on one patient before discontinuing therapy due to withdraw/refusal
        group Id
        FG000
        num Subjects
        34
      type
      Reported Adverse Events Data
    5. achievements
      1. comment
        Treatment continued until disease progression or intolerability.
        group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    6. achievements
      1. group Id
        FG000
        num Subjects
        35
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol R, patients had to have BRAF fusion or Non-V600E, Non-V600K mutations.
recruitment Details
Subprotocol R was activated on August 12, 2015. A total of 50 patients were assigned to this arm after screening, 48 from screening cohort and 2 from outside assay. Of the 50 patients, 35 patients were enrolled to arm R between December 4, 2015 and August 17, 2017.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice